Development of [64Cu]-Dota-Pr81 Radioimmunoconjugate for Muc-1 Positive Pet Imaging Publisher Pubmed



Alirezapour B¹ ; Rasaee MJ² ; Jalilian AR¹ ; Rajabifar S¹ ; Mohammadnejad J³ ; Paknejad M⁴ ; Maadi E¹ ; Moradkhani S¹ Show Affiliations
Source: Nuclear Medicine and Biology Published:2016

Abstract

Objective: Breast cancer radioimmunoscintigraphy targeting MUC1 expression is a growing field of work in nuclear medicine research. PR81 is a monoclonal antibody that binds with high affinity to MUC1, which is over expressed on breast tumors. In this study, we report production, quality control and preclinical qualifications of a copper-64 labeled PR81 for PET imaging of breast cancer. Methods: PR81 was conjugated with DOTA-NHS-ester and purified by molecular filtration followed by chelate:mAb ratio determination by spectrophotometric method. DOTA-PR81 was labeled with 64Cu followed by radiochemical purity, in vitro stability, in vitro internalization and immunoreactivity determination. The tissue biodistribution of the 64Cu-DOTA-PR81 and 64Cu-DOTA-hIgG was evaluated in BALB/c mice with breast carcinoma tumors using tissue counting and imaging. Results: The radiochemical purity of radioimmunoconjugate was >95±1.9% (ITLC) (specific activity; 4.6μCi/μg). The average number of chelators per antibody was 3.4±0.3:1. The 64Cu-DOTA-PR81 showed immunoreactivity towards MUC1 antigen and MCF7 cell line with significant in vitro stability (>89% in PBS and 78±0.5% in human serum) over 48h. Maximum internalized activity of radiolabeled PR81 in 4-8h was 81.5%. The biodistribution and scintigraphy studies showed the accumulation of the complex at the site of tumors with high sensitivity and specificity compared to control probes. Conclusion: The results showed that 64Cu-DOTA-PR81 may be considered as a potential PET tracer for diagnosis and follow-up of MUC1 expression in oncology. © 2015 Elsevier Inc.